Biochemical markers of liver fibrosis: A comparison with historical features in patients with chronic hepatitis C

American Journal of Gastroenterology

Volumn 97, Issue 9, 2002, Pages 2419-2425

  Myers, Robert P ^a   Ratziu, Vlad ^a   Imbert Bismut, Françoise ^a   Charlotte, Frédéric ^a   Poynard, Thierry ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; BILIRUBIN; BIOCHEMICAL MARKER; GAMMA GLUTAMYLTRANSFERASE; HAPTOGLOBIN;

ACCURACY; ADULT; AGE; ALCOHOL CONSUMPTION; ARTICLE; COMPARATIVE STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FEMALE; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE;

EID: 0036734486     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(02)04354-X     Document Type: Article

References (26)

1. Hepatitis C virus infection
2. Which patients with hepatitis C develop liver complications?
3. EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement
4. The role of liver biopsy in hepatitis C
5. Practices of liver biopsy in France: Results of a prospective nationwide survey
6. Practice and complications of liver biopsy. Results of a nationwide survey in Switzerland
7. A 21-year experience with major hemorrhage after percutaneous liver biopsy
8. Liver biopsy: Complications in 1000 inpatients and outpatients
9. An algorithm for the grading of activity in chronic hepatitis C
10. Mechanisms and therapy of hepatic fibrosis: Report of the AASLD Single Topic Basic Research Conference
11. Evaluation of fibrosis and hepatitis C
12. Aspartate aminotransferase: Alanine aminotransferase ratio in chronic hepatitis C infection: Is it a useful predictor of cirrhosis?
13. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as non-invasive markers of liver disease in chronic hepatitis C: Comparison using ROC analysis
14. Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection
15. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study
16. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C
17. Natural history of liver fibrosis progression in patients with chronic hepatitis C
18. Historical features are poor predictors of liver fibrosis in Canadian patients with chronic hepatitis C
19. Epidemiology of hepatitis C
20. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C
21. National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C
22. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt
23. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
24. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
25. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: Longitudinal validation in a randomized trial
26. Estimating the date of hepatitis C virus (HCV) infection among Alaska native blood transfusion recipients and intravenous drug users (IDU): Comparison between data from patient interviews and antibody tests using stored sera